open access

Vol 65, No 5 (2014)
Original papers
Published online: 2014-10-09
Submitted: 2014-10-10
Accepted: 2014-10-10
Get Citation

Transforming Growth Factor β1 (TGFβ1) and Vascular Endothelial Growth Factor (VEGF) in the blood of healthy people and patients with Graves’ orbitopathy — a new mechanism of glucocorticoids action?

Dariusz Kajdaniuk, Bogdan Marek, Danuta Niedziołka-Zielonka, Wanda Foltyn, Mariusz Nowak, Lucyna Siemińska, Halina Borgiel-Marek, Joanna Głogowska-Szeląg, Zofia Ostrowska, Lucjan Drożdż, Beata Kos-Kudła
DOI: 10.5603/EP.2014.0048
·
Endokrynologia Polska 2014;65(5):348-356.

open access

Vol 65, No 5 (2014)
Original papers
Published online: 2014-10-09
Submitted: 2014-10-10
Accepted: 2014-10-10

Abstract

Introduction: The first part of this paper is related to healthy people and presents concentrations of TGFβ1 and VEGF in blood (with and without dividing data with respect to sex), their single measurement values (at 8 am), Mean Daily Concentrations (MDC), Area Under the Curves (AUC; total daily secretion), and circadian rhythm. The second part of the work is related to Graves’ orbitopathy (GO). The aim of the study were: 1) to determine the physiological pattern of TGFβ1 and VEGF secretion; 2) to compare the serum TGFβ1 and VEGF circadian profile in newly diagnosed thyreotoxic patients with active GO and healthy controls (H); and 3) to estimate the influence of high-dose intravenous methylprednisolone pulse therapy (MP) on TGFb1 and VEGF blood levels in GO.

Material and methods: Twenty-two healthy (H) subjects and 16 hyperthyroid GO patients were treated with MP (6 g/14 days) and followed up by ophthalmological assessment. Blood was collected before and after 2 weeks MP-therapy. TGFβ1 and VEGF levels were determined by the ELISA method.

Results: No difference was observed in the concentrations of TGFβ1 and VEGF in the blood of healthy women and men — in further analysis, a combined healthy male and female cohort was used (H). While the absence of circadian rhythms in the concentrations of TGFβ1 and VEGF allows the application of a single measurement approach, MDC and AUC measurements were found to be more precise. There were no differences in TGFβ1 MDC/AUC between GO and H. VEGF MDC/AUC in GO were higher than in H. MP-therapy increased TGFb1 MDC/AUC, thus in GO after MP, the TGFβ1 MDC/AUC were higher than in H. There were no differences in VEGF MDC/AUC during MP-therapy. MP-therapy was effective in 15/16 patients.

Conclusions:

1. MP-therapy increases MDC and AUC of TGFβ1. The effectiveness of MP-therapy in patients with active GO may be related to its influence on TGFβ1 concentrations in blood. The results suggest the existence of a new mechanism of glucocorticoids action, consisting of an increase in the secretion of TGFβ1.

2. The elevated serum VEGF in thyreotoxic patients with active GO may reflect long-standing autoimmune processes in orbital and thyroid tissues and intensified angiogenesis in the thyroid gland. (Endokrynol Pol 2014; 65 (5): 348–356)

Abstract

Introduction: The first part of this paper is related to healthy people and presents concentrations of TGFβ1 and VEGF in blood (with and without dividing data with respect to sex), their single measurement values (at 8 am), Mean Daily Concentrations (MDC), Area Under the Curves (AUC; total daily secretion), and circadian rhythm. The second part of the work is related to Graves’ orbitopathy (GO). The aim of the study were: 1) to determine the physiological pattern of TGFβ1 and VEGF secretion; 2) to compare the serum TGFβ1 and VEGF circadian profile in newly diagnosed thyreotoxic patients with active GO and healthy controls (H); and 3) to estimate the influence of high-dose intravenous methylprednisolone pulse therapy (MP) on TGFb1 and VEGF blood levels in GO.

Material and methods: Twenty-two healthy (H) subjects and 16 hyperthyroid GO patients were treated with MP (6 g/14 days) and followed up by ophthalmological assessment. Blood was collected before and after 2 weeks MP-therapy. TGFβ1 and VEGF levels were determined by the ELISA method.

Results: No difference was observed in the concentrations of TGFβ1 and VEGF in the blood of healthy women and men — in further analysis, a combined healthy male and female cohort was used (H). While the absence of circadian rhythms in the concentrations of TGFβ1 and VEGF allows the application of a single measurement approach, MDC and AUC measurements were found to be more precise. There were no differences in TGFβ1 MDC/AUC between GO and H. VEGF MDC/AUC in GO were higher than in H. MP-therapy increased TGFb1 MDC/AUC, thus in GO after MP, the TGFβ1 MDC/AUC were higher than in H. There were no differences in VEGF MDC/AUC during MP-therapy. MP-therapy was effective in 15/16 patients.

Conclusions:

1. MP-therapy increases MDC and AUC of TGFβ1. The effectiveness of MP-therapy in patients with active GO may be related to its influence on TGFβ1 concentrations in blood. The results suggest the existence of a new mechanism of glucocorticoids action, consisting of an increase in the secretion of TGFβ1.

2. The elevated serum VEGF in thyreotoxic patients with active GO may reflect long-standing autoimmune processes in orbital and thyroid tissues and intensified angiogenesis in the thyroid gland. (Endokrynol Pol 2014; 65 (5): 348–356)

Get Citation

Keywords

TGFbeta1; VEGF; transforming growth factor beta 1; vascular-endothelial growth factor; healthy; thyroid; Graves; orbitopathy; fibrosis; angiogenesis; methylprednisolone; glucocorticoids

About this article
Title

Transforming Growth Factor β1 (TGFβ1) and Vascular Endothelial Growth Factor (VEGF) in the blood of healthy people and patients with Graves’ orbitopathy — a new mechanism of glucocorticoids action?

Journal

Endokrynologia Polska

Issue

Vol 65, No 5 (2014)

Pages

348-356

Published online

2014-10-09

DOI

10.5603/EP.2014.0048

Bibliographic record

Endokrynologia Polska 2014;65(5):348-356.

Keywords

TGFbeta1
VEGF
transforming growth factor beta 1
vascular-endothelial growth factor
healthy
thyroid
Graves
orbitopathy
fibrosis
angiogenesis
methylprednisolone
glucocorticoids

Authors

Dariusz Kajdaniuk
Bogdan Marek
Danuta Niedziołka-Zielonka
Wanda Foltyn
Mariusz Nowak
Lucyna Siemińska
Halina Borgiel-Marek
Joanna Głogowska-Szeląg
Zofia Ostrowska
Lucjan Drożdż
Beata Kos-Kudła

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl